Pancreatic Cancer Research

ResearcherSt George's HospitalActive in the last 2 years

Angus George Dalgleish

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-3511-3059; OpenAlex author ID A5067606220. Sources: ClinicalTrials.gov.

Their work

Papers
9 (first author 2, last author 1)
Trials
1 (principal investigator on 1)
Grants
0
Labs led
0
Collaborators
18
Papers, trials and grants by year

2011: 1 paper, 1 trial · 2012: none · 2013: 1 paper · 2014: 1 paper · 2015: none · 2016: 2 papers · 2017: none · 2018: 1 paper · 2019: none · 2020: 2 papers · 2021: none · 2022: none · 2023: none · 2024: none · 2025: none · 2026: 1 paper

Papers 9

  1. [Corrigendum] Acquired resistance of pancreatic cancer cells to treatment with gemcitabine and HER‑inhibitors is accompanied by increased sensitivity to STAT3 … Co-author DOI 10.3892/ijo.2026.5948↗
  2. Development and application of two novel monoclonal antibodies against overexpressed CD26 and integrin α3 in human pancreatic cancer. First author DOI 10.1038/s41598-019-57287-w↗
  3. Synergistic activity of agents targeting growth factor receptors, CDKs and downstream signaling molecules in a panel of pancreatic cancer cell lines and the id… Co-author DOI 10.3892/or.2020.7822↗
  4. Development of novel monoclonal antibodies against CD109 overexpressed in human pancreatic cancer. First author DOI 10.18632/oncotarget.25017↗
  5. Randomised, open-label, phase II study of gemcitabine with and without IMM-101 for advanced pancreatic cancer. Co-author DOI 10.1038/bjc.2016.271↗
  6. Acquired resistance of pancreatic cancer cells to treatment with gemcitabine and HER-inhibitors is accompanied by increased sensitivity to STAT3 inhibition. Co-author DOI 10.3892/ijo.2016.3320↗
  7. IMM-101, an immunotherapeutic agent in clinical development as an adjunctive treatment for pancreatic cancer Co-author DOI 10.1186/2051-1426-2-s3-p83↗
  8. Treatment with a combination of the ErbB (HER) family blocker afatinib and the IGF-IR inhibitor, NVP-AEW541 induces synergistic growth inhibition of human panc… Co-author DOI 10.1186/1471-2407-13-41↗
  9. Mechanisms underlying gemcitabine resistance in pancreatic cancer and sensitisation by the iMiD™ lenalidomide. Last author PMID 22110196↗

Trials 1

  1. A Trial Comparing Gemcitabine With and Without IMM-101 in Advanced Pancreatic Cancer Principal investigator NCT01303172↗

Closest collaborators

The 18 strongest of 18 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Helmout Modjtahedi · 6 shared papers, 2013–2026 · strength 0.83
  2. Nikolaos Ioannou · 4 shared papers, 2013–2026 · strength 0.60
  3. Satvinder Mudan · 4 shared papers, 2016–2020 · strength 0.40
  4. Gustavo A. Arias-Pinilla · 2 shared papers, 2018–2020 · strength 0.23
  5. Tanzeel Khan · 1 shared paper, 2020 · strength 0.13
  6. Laura Rosa Brunet · 1 shared paper, 2014 · strength 0.06
  7. Hilary Bilyard · 1 shared paper, 2014 · strength 0.06
  8. Frances Macintosh · 1 shared paper, 2014 · strength 0.06
  9. Andrés Jesús Muñoz Martín · 1 shared paper, 2016 · strength 0.04
  10. Justin Stebbing · 1 shared paper, 2016 · strength 0.04
  11. Demetris Papamichael · 1 shared paper, 2016 · strength 0.04
  12. Douglas J.A. Adamson · 1 shared paper, 2016 · strength 0.04
  13. Ray McDermott · 1 shared paper, 2016 · strength 0.04
  14. Robert Díaz Beveridge · 1 shared paper, 2016 · strength 0.04
  15. Roberto Pazo-Cid · 1 shared paper, 2016 · strength 0.04
  16. David Kuang-Fu Chang · 1 shared paper, 2016 · strength 0.04
  17. Alberto Zaniboni · 1 shared paper, 2016 · strength 0.04
  18. Rosemary A Fryer · 1 shared paper, 2011 · strength 0.04

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.